long intergenic non-protein coding RNA 1209Genealiases: []
Q-omics provides the consensus-scored LINC01209 profile across patient tissues and cancer cell-line models. LINC01209 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LINC01209 is differentially expressed in 4, with the highest sampling consensus in BLCA. Additionally, LINC01209 RNA expression shows 5,909 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, BLCA, and STAD as cancer lineages where LINC01209 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01209 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01209 survival associations across molecular data types. LINC01209 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01209 RNA expression–survival associations across cancer types. High LINC01209 expression shows unfavorable associations in UVM, UCEC, SKCM, ACC and OV, but favorable associations in LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LINC01209 RNA expression.
This table summarizes LINC01209 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01209. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01209 shows higher tumor expression in BLCA, LUSC, BRCA and KICH. The BLCA box plot shows higher LINC01209 RNA expression in tumor versus normal tissue (log2 FC = +0.015, t-test p = .029).
This table shows molecular features associated with LINC01209 in patient tissues and cancer cell lines. In patient samples, LINC01209 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
